$FLGT News

Fulgent Genetics, Inc. 2026 Q2 - Results - Earnings Call Presentation

Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $19

Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript

Fulgent Genetics (NASDAQ:FLGT) Plunges 10.6% After Q2 Miss and Guidance Cut

Fulgent Genetics Lowers FY2026 Adj EPS Guidance from $(1.59) to $(2.35)-$(2.22) vs $(1.55) Est; Lowers FY2026 Sales Guidance from $350.000M to $330.000M-$340.000M vs $351.900M Est

Fulgent Genetics Q2 Adj. EPS $(0.58) Misses $(0.46) Estimate, Sales $85.389M Miss $94.000M Estimate

Fulgent Genetics: Strong Moves By Management Keep Me Bullish

Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

Fulgent Genetics (FLGT) Stock Faces Mixed Analyst Target Changes After Margin Questions

How The Fulgent Genetics (FLGT) Investment Story Is Evolving With Recent Developments

Fulgent Genetics' FID-007 Plus Cetuximab Shows 60% Response Rate And 7.2-Month Median PFS In Phase 2 Head And Neck Cancer Study With Favorable Safety Profile

Piper Sandler Reiterates Neutral on Fulgent Genetics, Lowers Price Target to $15

Fulgent Genetics (NASDAQ:FLGT) Shares Dip Premarket After Q1 Earnings Miss Despite Revenue Beat

Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript

Full Transcript: Fulgent Genetics Q1 2026 Earnings Call

Fulgent Genetics: A Major Market Misconception

Fulgent Genetics, Inc. 2025 Q4 - Results - Earnings Call Presentation

Fulgent Genetics, Inc. (FLGT) Q4 2025 Earnings Call Transcript

Fulgent Genetics (NASDAQ:FLGT) Shares Plunge on Weak 2026 Outlook After Mixed Q4

Fulgent Genetics shares are trading lower after the company reported mixed Q4 financial results. The company also issued FY26 guidance below estimates.